NYMC Faculty Publications
Evidence-Based Management of Arrhythmogenic Right Ventricular Cardiomyopathy in Pregnancy
Author Type(s)
Faculty
DOI
10.2217/fca-2020-0127
Journal Title
Future Cardiology
First Page
693
Last Page
703
Document Type
Article
Publication Date
7-2021
Department
Medicine
Abstract
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder resulting in fibrofatty replacement of the myocardium. Genetic mutations in genes encoding for desmosome proteins result in a ventricular myocardium prone to arrhythmias and heart failure. Although ARVC is known for a few decades, most of the outcomes in pregnancy are reported recently. Pregnancy leads to significant physiological changes with excess mechanical stress on the myocardium. All the retrospective studies suggest that pregnancy is well tolerated in these patients despite the high risk of arrhythmias and heart failure. Our review focuses on the most up-to-date evidence on the management of ARVC patients during the antepartum and postpartum period.
Recommended Citation
Khosla, J., Golamari, R., Cai, A., Benson, J., Aronow, W. S., Jain, R., & Jain, R. (2021). Evidence-Based Management of Arrhythmogenic Right Ventricular Cardiomyopathy in Pregnancy. Future Cardiology, 17 (4), 693-703. https://doi.org/10.2217/fca-2020-0127
